bioAffinity Tech Stock Price, News & Analysis

bioAffinity Technologies (Nasdaq: BIAF) reported record CyPath® Lung test volumes in Q3 2025, with sales up 95% versus Q2 2025 and a 97% increase in sales for the first nine months of 2025 versus the same period in 2024. The company cited growing adoption by Veterans’ hospitals and expansion in the mid-Atlantic region.

Management highlighted a 77% increase in new patients using CyPath® Lung in Q3 and improved at-home sample collection compliance. Published case studies cited earlier detection (including Stage 1A) and fewer unnecessary invasive procedures.

bioAffinity Technologies (NASDAQ: BIAF) has completed its previously announced public offering, raising $4.8 million in gross proceeds. The offering consisted of 1,921,761 shares of Common Stock (or pre-funded warrants) priced at $2.50 per share ($2.493 per pre-funded warrant).

WallachBeth Capital LLC served as the sole placement agent for the offering. The pre-funded warrants have an exercise price of $0.007 per share and will expire when exercised in full. The offering was conducted pursuant to an effective registration statement on Form S-1 filed with the SEC.

bioAffinity Technologies (NASDAQ: BIAF), a biotechnology company focused on early-stage cancer detection, has completed its previously announced public offering, raising $4.8 million in gross proceeds. The offering included 1,921,761 shares of Common Stock (or pre-funded warrants) priced at $2.50 per share ($2.493 for pre-funded warrants).

The pre-funded warrants have an exercise price of $0.007 per share and will expire upon full exercise. WallachBeth Capital, LLC served as the sole placement agent for this offering, which was conducted under an effective SEC registration statement on Form S-1.

bioAffinity Technologies (NASDAQ: BIAF, BIAFW), a biotechnology company developing early-stage cancer detection tests, has announced pricing for a $4.8 million public offering. The offering consists of 1,921,799 shares of common stock (or pre-funded warrants) priced at $2.50 per share (or $2.493 per pre-funded warrant).

The pre-funded warrants will have an exercise price of $0.007 per share and will be immediately exercisable until fully exercised. WallachBeth Capital LLC is serving as the sole placement agent, with the offering expected to close around September 30, 2025.

bioAffinity Technologies (NASDAQ: BIAF), a biotechnology company focused on early-stage cancer detection, has announced pricing for a $4.8 million public offering. The offering consists of 1,921,799 shares of Common Stock (or pre-funded warrants) at $2.50 per share ($2.493 per pre-funded warrant).

The pre-funded warrants will have an exercise price of $0.007 per share and will be immediately exercisable until fully exercised. WallachBeth Capital, LLC is serving as the sole placement agent, with the offering expected to close around September 30, 2025.

bioAffinity Technologies (NASDAQ: BIAF) has released three new case studies demonstrating the clinical effectiveness of its CyPath® Lung noninvasive diagnostic test for lung cancer. The studies showcase how the test aids in critical clinical decision-making, with one case leading to early Stage 1A lung cancer detection and two cases helping avoid unnecessary invasive procedures.

The highlighted cases include: "Samuel," where a positive CyPath® Lung result convinced a hesitant patient to proceed with a biopsy, leading to early cancer detection; "David," where a negative result helped avoid an unnecessary biopsy; and "Lisa," where a positive result supported the decision to proceed with radiation treatment without a risky biopsy in a patient with end-stage COPD.

bioAffinity Technologies (NASDAQ: BIAF) has announced a 1-for-30 reverse stock split effective September 19, 2025. The split was approved by stockholders on July 25, 2025, and aims to bring the company into compliance with Nasdaq's minimum bid price requirement.

Following the split, the company will have approximately 1,338,029 shares outstanding. Stockholders will receive one share for every 30 shares held, with cash payments for fractional shares. Proportionate adjustments will be made to stock options, incentive plans, and outstanding warrants. The company's transfer agent, VStock Transfer LLC, will manage the exchange process.

bioAffinity Technologies (NASDAQ: BIAF) released a case study demonstrating the effectiveness of its CyPath® Lung diagnostic test in identifying lung cancer in a patient with ground-glass pulmonary nodules. The test successfully detected cancer in a 66-year-old former smoker who had multiple ground-glass nodules discovered during an unrelated CT scan.

The case highlights CyPath® Lung's ability to provide actionable results that can expedite treatment decisions, particularly in cases where traditional guidelines recommend 2-5 years of watchful waiting. Following the "likely malignant" test result, robotic bronchoscopy confirmed the cancer diagnosis, leading to immediate surgical treatment referral.

bioAffinity Technologies (NASDAQ:BIAF) received recognition from U.S. Medicine magazine for its CyPath® Lung diagnostic test, highlighting its potential to improve lung cancer detection in veterans while reducing VA healthcare costs. The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting nodules 20mm or smaller.

Research published in the Journal of Health Economics and Outcomes Research revealed potential savings of $895 million for private payers and $379 million for Medicare if CyPath® Lung had been integrated into the standard of care in 2022. The test has successfully detected lung cancer at Stage 1A when other diagnostic tools failed.